Th1, Th17, CXCL16 and homocysteine elevated after intracranial and cervical stent implantation

References

• Johnston SC, Mendis S, Mathers CD. Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling. Lancet Neurol 2009;8:345–54.
   PubMed Web of Science ®Google Scholar
• Wang C, Li J, Zhao X, et al. Stroke care development in Mainland China: past, present and future. Int J Stroke 2008;3:288–9.
   PubMed Web of Science ®Google Scholar
• Kolominsky-Rabas PL, Weber M, Gefeller O, et al. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke 2001;32:2735–40.
   PubMed Web of Science ®Google Scholar
• Niccoli G, Montone RA, Ferrante G, et al. The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol 2010;56:1783–93.
   PubMed Web of Science ®Google Scholar
• Dimayuga PC, Chyu KY, Lio WM, et al. Reduced neointima formation after arterial injury in CD4-/- mice is mediated by CD8+CD28hi T cells. J Am Heart Assoc 2013;2:e000155.
   Web of Science ®Google Scholar
• Zhu J, Paul WE. Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors. Immunol Rev 2010;238:247–62.
   PubMed Web of Science ®Google Scholar
• Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009;9:271–85.
   PubMed Web of Science ®Google Scholar
• Wang Y, Bai Y, Qin L, et al. Interferon-gamma induces human vascular smooth muscle cell proliferation and intimal expansion by phosphatidylinositol 3-kinase dependent mammalian target of rapamycin raptor complex 1 activation. Circ Res 2007;101:560–9.
   PubMed Web of Science ®Google Scholar
• Hansson GK, Holm J. Interferon-gamma inhibits arterial stenosis after injury. Circulation 1991;84:1266–72.
   PubMed Web of Science ®Google Scholar
• Castronuovo JJ, Jr., Guss SB, Mysh D, et al. Cytokine therapy for arterial restenosis: inhibition of neointimal hyperplasia by gamma-interferon. Cardiovasc Surg 1995;3:463–8.
   PubMedGoogle Scholar
• Ivanov, II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006;126:1121–33.
   PubMed Web of Science ®Google Scholar
• Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR. Autoimmune inflammation from the Th17 perspective. Autoimmun Rev 2007;6:169–75.
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32:2045–51.
   PubMed Web of Science ®Google Scholar
• Liu Z, Lu F, Pan H, et al. Correlation of peripheral Th17 cells and Th17-associated cytokines to the severity of carotid artery plaque and its clinical implication. Atherosclerosis 2012;221:232–41.
   PubMed Web of Science ®Google Scholar
• Abel S, Hundhausen C, Mentlein R, et al. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol (Baltimore, Md: 1950) 2004;172:6362–72.
   PubMed Web of Science ®Google Scholar
• Matloubian M, David A, Engel S, et al. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol 2000;1:298–304.
   PubMed Web of Science ®Google Scholar
• Zivkovic M, Djuric T, Stojkovic L, et al. CXCL16 haplotypes in patients with human carotid atherosclerosis: preliminary results. J Atheroscler Thromb 2015;22:10–20.
   PubMed Web of Science ®Google Scholar
• Ma A, Pan X, Xing Y, et al. Elevation of serum CXCL16 level correlates well with atherosclerotic ischemic stroke. Arch Med Sci 2014;10:47–52.
   PubMed Web of Science ®Google Scholar
• De Luca G, Suryapranata H, Gregorio G, et al. Homocysteine and its effects on in-stent restenosis. Circulation 2005;112:e307–11.
   PubMed Web of Science ®Google Scholar
• Wang S, Ni B, Chen K, et al. Influences of cerebral stent implantation on CD4CD25FOXP3Treg, Th1 and Th17 cells. Int Immunopharmacol 2013;17:519–25.
   PubMed Web of Science ®Google Scholar
• Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998;339:1415–25.
   PubMed Web of Science ®Google Scholar
• Simon DI. Inflammation and vascular injury: basic discovery to drug development. Circulation J 2012;76:1811–8.
   PubMed Web of Science ®Google Scholar
• Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001;103:1718–20.
   PubMed Web of Science ®Google Scholar
• Marcus AJ. Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. Semin Hematol 1994;31:261–9.
   PubMed Web of Science ®Google Scholar
• Forrester JS, Fishbein M, Helfant R, et al. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991;17:758–69.
   PubMed Web of Science ®Google Scholar
• Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99:44–52.
   PubMed Web of Science ®Google Scholar
• Xie JJ, Wang J, Tang TT, et al. The Th17/Treg functional imbalance during atherogenesis in ApoE(-/-) mice. Cytokine 2010;49:185–93.
   PubMed Web of Science ®Google Scholar
• Potekhina AV, Pylaeva E, Provatorov S, et al. Treg/Th17 balance in stable CAD patients with different stages of coronary atherosclerosis. Atherosclerosis 2015;238:17–21.
   PubMed Web of Science ®Google Scholar
• Gaspardone A, Versaci F. Coronary stenting and inflammation. Am J Cardiol 2005;96:65L–70L.
   PubMed Web of Science ®Google Scholar
• Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030–9.
   PubMed Web of Science ®Google Scholar
• Minami M, Kume N, Shimaoka T, et al. Expression of scavenger receptor for phosphatidylserine and oxidized lipoprotein (SR-PSOX) in human atheroma. Ann N Y Acad Sci 2001;947:373–6.
   PubMed Web of Science ®Google Scholar
• Wuttge DM, Zhou X, Sheikine Y, et al. CXCL16/SR-PSOX is an interferon-gamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2004;24:750–5.
   PubMed Web of Science ®Google Scholar
• Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. J Am Med Assoc 2005;293:2126–30.
   PubMed Web of Science ®Google Scholar
• McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519–21.
   PubMed Web of Science ®Google Scholar
• Postea O, Koenen RR, Hristov M, et al. Homocysteine up-regulates vascular transmembrane chemokine CXCL16 and induces CXCR6+ lymphocyte recruitment in vitro and in vivo. J Cell Mol Med 2008;12:1700–9.
   PubMed Web of Science ®Google Scholar
• Latta M, Mohan K, Issekutz TB. CXCR6 is expressed on T cells in both T helper type 1 (Th1) inflammation and allergen-induced Th2 lung inflammation but is only a weak mediator of chemotaxis. Immunology 2007;121:555–64.
   PubMed Web of Science ®Google Scholar
• Butcher MJ, Wu CI, Waseem T, et al. CXCR6 regulates the recruitment of pro-inflammatory IL-17A-producing T cells into atherosclerotic aortas. Int Immunol 2016;28:255–61.
   PubMed Web of Science ®Google Scholar
• Ye ZJ, Zhou Q, Yin W, et al. Interleukin 22-producing CD4+ T cells in malignant pleural effusion. Cancer Lett 2012;326:23–32.
   PubMed Web of Science ®Google Scholar